Links for fulltext
     (May Require Subscription)

Conference Paper: Histological outcome after liver transplantation for chronic hepatitis B using oral antiviral therapy alone without hepatitis B immune globulin

TitleHistological outcome after liver transplantation for chronic hepatitis B using oral antiviral therapy alone without hepatitis B immune globulin
Authors
KeywordsMedical sciences
Gastroenterology medical sciences
Surgery
Issue Date2014
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
Citation
The 2014 Joint International Congress of ILTS, ELITA and LICAGE, London, UK., 4-7 June 2014. In Liver Transplantation, 2014, v. 20 suppl. S1, p. S134, abstract O-97 How to Cite?
AbstractAIM: To determine the histological outcome after liver transplantation for patients with chronic hepatitis B (CHB) receiving oral antiviral therapy without hepatitis B immune globulin (HBIG). METHODS: All patients transplanted for CHB-related complications from January 2003 to December 2012 were included. None of the patients received HBIG. All biopsies performed 3 months after transplantation were analyzed. Biopsies were performed on the basis of graft dysfunction. Immunohistochemical study with anti-hepatitis B surface antigen (HBsAg) antibody was performed. RESULTS: A total of 440 CHB patients underwent liver transplantation with a median follow-up of 58 months (range, 0-130). Of these, 139 (31.6%) patients underwent liver biopsy for graft dysfunction, with a total of 258 biopsies performed. The median time to biopsy was 10 months (range, 3-104). Forty-five patients had positive serum HBsAg at the time of biopsy, of which 6 were positive for HBsAg stain. All 6 patients were on lamivudine with known virological rebound due to resistance. In the remaining 39 patients with negative HBsAg stain, 7 patients had grade 1 fibrosis from non-HBV related causes. Forty patients were on entecavir monotherapy, of which 9 patients were positive for serum HBsAg at the time of biopsy and all were negative for HBsAg staining; only 1 had grade 1 fibrosis from non-hepatitis B cause. In the remaining 94 patients who were HBsAg-negative at the time of biopsy, none had histological evidence of recurrence of hepatitis B. CONCLUSION: For patients without virological rebound, positive serum HBsAg was not associated with histological evidence of recurrent hepatitis B infection after liver transplantation. For patients receiving entecavir monotherapy, no histological evidence of recurrent hepatitis B was observed irrespective of the serum HBsAg status.
DescriptionOral Abstract Session - Recurrent Disease/Pathology: O-97
Young Investigator Awards: James Fung
This journal suppl. entitled: The ILTS 20th Annual International Congress
Persistent Identifierhttp://hdl.handle.net/10722/206846
ISSN
2015 Impact Factor: 3.951
2015 SCImago Journal Rankings: 1.763

 

DC FieldValueLanguage
dc.contributor.authorFung, J-
dc.contributor.authorLo, R-
dc.contributor.authorChan, SC-
dc.contributor.authorChok, KSH-
dc.contributor.authorSharr, WW-
dc.contributor.authorDai, WC-
dc.contributor.authorCheung, TT-
dc.contributor.authorChan, ACY-
dc.contributor.authorWong, T-
dc.contributor.authorNg, IOL-
dc.contributor.authorYuen, MF-
dc.contributor.authorLo, CM-
dc.date.accessioned2014-12-02T10:28:24Z-
dc.date.available2014-12-02T10:28:24Z-
dc.date.issued2014-
dc.identifier.citationThe 2014 Joint International Congress of ILTS, ELITA and LICAGE, London, UK., 4-7 June 2014. In Liver Transplantation, 2014, v. 20 suppl. S1, p. S134, abstract O-97-
dc.identifier.issn1527-6465-
dc.identifier.urihttp://hdl.handle.net/10722/206846-
dc.descriptionOral Abstract Session - Recurrent Disease/Pathology: O-97-
dc.descriptionYoung Investigator Awards: James Fung-
dc.descriptionThis journal suppl. entitled: The ILTS 20th Annual International Congress-
dc.description.abstractAIM: To determine the histological outcome after liver transplantation for patients with chronic hepatitis B (CHB) receiving oral antiviral therapy without hepatitis B immune globulin (HBIG). METHODS: All patients transplanted for CHB-related complications from January 2003 to December 2012 were included. None of the patients received HBIG. All biopsies performed 3 months after transplantation were analyzed. Biopsies were performed on the basis of graft dysfunction. Immunohistochemical study with anti-hepatitis B surface antigen (HBsAg) antibody was performed. RESULTS: A total of 440 CHB patients underwent liver transplantation with a median follow-up of 58 months (range, 0-130). Of these, 139 (31.6%) patients underwent liver biopsy for graft dysfunction, with a total of 258 biopsies performed. The median time to biopsy was 10 months (range, 3-104). Forty-five patients had positive serum HBsAg at the time of biopsy, of which 6 were positive for HBsAg stain. All 6 patients were on lamivudine with known virological rebound due to resistance. In the remaining 39 patients with negative HBsAg stain, 7 patients had grade 1 fibrosis from non-HBV related causes. Forty patients were on entecavir monotherapy, of which 9 patients were positive for serum HBsAg at the time of biopsy and all were negative for HBsAg staining; only 1 had grade 1 fibrosis from non-hepatitis B cause. In the remaining 94 patients who were HBsAg-negative at the time of biopsy, none had histological evidence of recurrence of hepatitis B. CONCLUSION: For patients without virological rebound, positive serum HBsAg was not associated with histological evidence of recurrent hepatitis B infection after liver transplantation. For patients receiving entecavir monotherapy, no histological evidence of recurrent hepatitis B was observed irrespective of the serum HBsAg status.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021-
dc.relation.ispartofLiver Transplantation-
dc.rightsLiver Transplantation. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectGastroenterology medical sciences-
dc.subjectSurgery-
dc.titleHistological outcome after liver transplantation for chronic hepatitis B using oral antiviral therapy alone without hepatitis B immune globulin-
dc.typeConference_Paper-
dc.identifier.emailFung, J: jfung@hkucc.hku.hk-
dc.identifier.emailLo, R: loregina@hku.hk-
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hk-
dc.identifier.emailChok, KSH: chok6275@hku.hk-
dc.identifier.emailSharr, WW: wwsharr@hku.hk-
dc.identifier.emailDai, WC: daiwc@hku.hk-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailChan, ACY: acchan@hku.hk-
dc.identifier.emailWong, T: wongtcl@hku.hk-
dc.identifier.emailNg, IOL: iolng@hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.authorityFung, J=rp00518-
dc.identifier.authorityLo, R=rp01359-
dc.identifier.authorityChan, SC=rp01568-
dc.identifier.authorityChan, ACY=rp00310-
dc.identifier.authorityWong, T=rp01679-
dc.identifier.authorityNg, IOL=rp00335-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.authorityLo, CM=rp00412-
dc.identifier.doi10.1002/lt.23901-
dc.identifier.hkuros241546-
dc.identifier.volume20-
dc.identifier.issuesuppl. S1-
dc.identifier.spageS134, abstract O-97-
dc.identifier.epageS134, abstract O-97-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats